# Bristol-Myers Squibb (BMY) total debt: $47.14B in 2025

URL: https://funkfolio.com/stock/BMY/total-debt

> Bristol-Myers Squibb (BMY) total debt was $47.14B at the end of fiscal 2025, down 7.9% from fiscal 2024. Over five fiscal years it shrank 2.2% a year.

---

## Bristol-Myers Squibb (BMY) total debt

**Total debt · fiscal 2025:** $47.14B at Dec 31, 2025

Bristol-Myers Squibb (BMY) carried total debt of $47.14B at the end of fiscal 2025 (December 31, 2025). That is 7.9% lower than the $51.20B of fiscal 2024. Figures as of 18 Nov 2026, 05:28 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Total debt, fiscal 2025:** $47.14B
- **Change on fiscal 2024:** −7.9%
- **Growth, 5 years:** −2.2% a year
- **Growth, 10 years:** +21.3% a year
- **Highest on record:** $52.68B fiscal 2020
- **Lowest on record:** $5.45B fiscal 2010
- **Fiscal years on record:** 18 2008–2025

Figures as of 18 Nov 2026, 05:28 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Bristol-Myers Squibb total debt, in more detail

Over the five fiscal years to 2025 total debt shrank at a compound 2.2% a year; over ten years the rate was 21.3% a year. Across the 18 fiscal years on record (2008–2025), the highest was $52.68B in fiscal 2020 and the lowest $5.45B in fiscal 2010.

Total debt was 2.6× shareholders' equity at the end of fiscal 2025.

### Total debt by fiscal year

### Bristol-Myers Squibb total debt, year by year

Bristol-Myers Squibb (BMY) total debt by fiscal year

| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
| --- | --- | --- | --- | --- |
| 2025 | $47.14B | 7.9% down | Dec 31, 2025 | 2.6× |
| 2024 | $51.20B | 23.5% up | Dec 31, 2024 | 3.1× |
| 2023 | $41.46B | 1.8% up | Dec 31, 2023 | 1.4× |
| 2022 | $40.72B | 17.4% down | Dec 31, 2022 | 1.3× |
| 2021 | $49.32B | 6.4% down | Dec 31, 2021 | 1.4× |
| 2020 | $52.68B | 6.4% up | Dec 31, 2020 | 1.4× |
| 2019 | $49.50B | 475.7% up | Dec 31, 2019 | 1.0× |
| 2018 | $8.60B | 8.0% up | Dec 31, 2018 | 0.6× |
| 2017 | $7.96B | 21.1% up | Dec 31, 2017 | 0.7× |
| 2016 | $6.57B | 3.7% down | Dec 31, 2016 | 0.4× |
| 2015 | $6.83B | 18.9% down | Dec 31, 2015 | 0.5× |
| 2014 | $8.42B | 3.2% down | Dec 31, 2014 | 0.6× |
| 2013 | $8.70B | 17.6% up | Dec 31, 2013 | 0.6× |
| 2012 | $7.39B | 34.7% up | Dec 31, 2012 | 0.5× |
| 2011 | $5.49B | 0.8% up | Dec 31, 2011 | 0.3× |
| 2010 | $5.45B | 14.4% down | Dec 31, 2010 | 0.3× |
| 2009 | $6.36B | 5.6% down | Dec 31, 2009 | 0.4× |
| 2008 | $6.74B | — | Dec 31, 2008 | 0.6× |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

### How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

### Total debt at health care companies of similar size

Total debt of Bristol-Myers Squibb and comparable companies

| Company | Total debt | Fiscal year |
| --- | --- | --- |
| [Vertex Pharmaceuticals VRTX](https://funkfolio.com/stock/VRTX/total-debt) | $2.03B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/total-debt) | $27.96B | 2026 |
| Bristol-Myers Squibb BMY | $47.14B | 2025 |
| [Stryker SYK](https://funkfolio.com/stock/SYK/total-debt) | $15.86B | 2025 |
| [McKesson MCK](https://funkfolio.com/stock/MCK/total-debt) | $8.61B | 2026 |
| [Sanofi SNY](https://funkfolio.com/stock/SNY/total-debt) | €20.33B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Bristol-Myers Squibb, figure by figure

- [Bristol-Myers Squibb market cap](https://funkfolio.com/stock/BMY/market-cap)
- [Bristol-Myers Squibb revenue](https://funkfolio.com/stock/BMY/revenue)
- [Bristol-Myers Squibb earnings](https://funkfolio.com/stock/BMY/earnings)
- [Bristol-Myers Squibb earnings per share (EPS)](https://funkfolio.com/stock/BMY/eps)
- [Bristol-Myers Squibb P/E ratio](https://funkfolio.com/stock/BMY/pe-ratio)
- [Bristol-Myers Squibb P/S ratio](https://funkfolio.com/stock/BMY/ps-ratio)
- [Bristol-Myers Squibb P/B ratio](https://funkfolio.com/stock/BMY/pb-ratio)
- [Bristol-Myers Squibb free cash flow](https://funkfolio.com/stock/BMY/free-cash-flow)
- [Bristol-Myers Squibb operating margin](https://funkfolio.com/stock/BMY/operating-margin)
- [Bristol-Myers Squibb dividend](https://funkfolio.com/stock/BMY/dividend)
- [Bristol-Myers Squibb shares outstanding](https://funkfolio.com/stock/BMY/shares-outstanding)
- [Bristol-Myers Squibb cash on hand](https://funkfolio.com/stock/BMY/cash)
- [Bristol-Myers Squibb total assets](https://funkfolio.com/stock/BMY/total-assets)
- [Bristol-Myers Squibb return on equity (ROE)](https://funkfolio.com/stock/BMY/roe)
- [Bristol-Myers Squibb return on invested capital (ROIC)](https://funkfolio.com/stock/BMY/roic)

[Bristol-Myers Squibb (BMY) overview: price, valuation and scorecard](https://funkfolio.com/stock/BMY) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Bristol-Myers Squibb total debt: questions and answers

**How much debt does Bristol-Myers Squibb have?**

Bristol-Myers Squibb (BMY) carried total debt of $47.14B at the end of fiscal 2025 (December 31, 2025). That is 7.9% lower than the $51.20B of fiscal 2024.

**What is the growth rate of Bristol-Myers Squibb's total debt?**

Over the five fiscal years to 2025 total debt shrank at a compound 2.2% a year; over ten years the rate was 21.3% a year.

**What are the highest and lowest total debt figures on record for Bristol-Myers Squibb?**

Across the 18 fiscal years on record (2008–2025), the highest was $52.68B in fiscal 2020 and the lowest $5.45B in fiscal 2010.

**How does Bristol-Myers Squibb's debt compare with its equity?**

Total debt was 2.6× shareholders' equity at the end of fiscal 2025.

**How is Bristol-Myers Squibb's total debt calculated?**

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

### Learn: total debt

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Bristol-Myers Squibb (BMY) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/BMY/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.
